The trusted Bedrocan® flower soon available as Becanex PIEX concentrate for compounding

For the first time, the most prescribed Bedrocan® flower will be available to pharmacists as a concentrate for bespoke compounding. The product can be used for a versatile range of formulations, while maintaining the consistent quality trusted by doctors and patients for over 20 years. This is made possible through a long-term partnership and the combined expertise of Dutch pioneer Bedrocan and Berlin-based extraction specialist Becanex. The companies aim to start supplying the concentrate by the summer of 2026.

Becanex PIEX Bedrocan 70%

The first jointly developed cannabis extract is the Becanex PIEX Bedrocan® 70% THC Concentrate. Becanex PIEX Bedrocan® faithfully contains a fingerprint of the natural cannabinoid and terpene profile of the original Bedrocan® flower. By preserving this profile through Becanex’s proprietary extraction method, the extract delivers predictable, consistent results.

Versatility in patient-specific care

One of the defining strengths of the product is its standardised form and compounding versatility. The concentrate is specifically designed to be incorporated into a broad range of patient-specific preparations, including oral solutions, capsules, suppositories, topical forms, and inhalation dosages. The option to vaporize the concentrate is particularly significant as it will give patients an additional method of inhalation alongside the flower. The extensive range of options provides healthcare professionals and pharmacists with full flexibility in tailoring therapies to individual patient needs.

A partnership rooted in shared values

The collaboration between Bedrocan and Becanex is grounded in a shared philosophy: that cannabis, as a medical product, demands the same rigour, standardisation and transparency expected of any pharmaceutical ingredient. The two companies’ complementary expertise, Bedrocan in standardised cultivation and Becanex in plant-identical extraction, makes Becanex PIEX Bedrocan® a natural expression of that shared commitment. Bedrocan CEO Jaap Erkelens has high expectations for the collaboration and the product: “We have always been precise about how we grow our cannabis. Becanex is equally precise about how they extract it. That shared attention to detail is what makes this product worth putting in front of pharmacists, prescribers and patients. In addition, the concentrate now enables doctors to prescribe our main product Bedrocan® in multiple compounding formulations.”

“Patients who have found a cannabis strain that works well for them shouldn’t have to compromise if they need it in a different form. With Bedrocan as our partner, we can now offer prescribers exactly that, building on a strain they already know and trust. That we are here today is no coincidence: as early as 2014, the team around Becanex co-founder Eral Osmanoglou worked together with Bedrocan under a scientific license to develop the first extracts from the Bedrocan® flower. The regulatory framework for such a product wasn’t there back then — today, we are returning to those results and bringing them to market” says Sebastian Kamphorst, Director of Becanex GmbH.

Product collaboration – Cannabis Europe London & Medical Cannabis Conference in Berlin 2026

The launch of Becanex PIEX Bedrocan marks the beginning of a broader product collaboration between the two companies, with Germany as the first market to launch the product. Both companies will present their joint products to the public for the first time at two consecutive industry events: Cannabis Europa in London and the Medical Cannabis Congress in Berlin, taking place in the same week. We look forward to welcoming you at our booth.

Orders

The Becanex PIEX Bedrocan 70% THC concentrate will be available to order for pharmacies from summer 2026 onwards. Product information and technical documentation can be requested immediately.

For more information, contact our business team: